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CHAPTER I 
INTRODUCTION 
Man has long recognized a wide variety of changes that 
frequently occur in tandem with the menstrual cycle. Hip-
pocrates, the father of medicine, attributed delusions, 
mania, thoughts of suicide and other symptoms to "retained 
menstrual blood" in his treatise on "The Sickness of Vir-
gins" (Wichita Eagle-Beacon, 1986). 
Although these cyclical changes in women have long been 
recognized, the explanation for the wide range of behav-
ioral, emotional and physical symptoms that occur on a regu-
lar basis, month after month, between ovulation and menstru-
ation, has remained an enigma. There is no universally 
accepted clinical definition for the premenstrual symptoms 
and no lab test to aid diagnosis. As a result no one has 
been able to develop a unifying explanation for the possible 
causes of these symptoms or determine the best way to treat 
the problem. Researchers cannot even come to a consensus on 
what to call this symptom complex that occurs during the 
luteal phase of the menstrual cycle. 
Robert Frank, an American gynecologist, first coined 
the term premenstrual tension (PMT) for a group of symptoms 
occurring during the premenstruum (Frank, 1931). Greene and 
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Dalton (1953), proposed the term which is probably the most 
widely used today, the premenstrual syndrome (PMS), so 
called because of the cyclicity of the symptoms and their 
relationship to the premenstrual phase. Then Parker (1960) 
took Frank's original label and combined it with Greene and 
Dalton's modification and called this symptom complex the 
premenstrual tension syndrome. 
These terms imply one syndrome, but Moos (1968) found 
many clusters of premenstrual symptoms which suggested many 
syndromes. Because nervous tension is one of the most com-
mon complaints, Abraham (1983), in recognition of Frank's 
initial contribution, and to acknowledge the large number of 
syndromes Moos had identified, developed the term premen-
strual tension syndromes (PMTS). This is the term that will 
be used throughout this paper. 
Premenstrual Tension Syndromes 
Definition of PMTS 
In addition to the lack of unanimity regarding what to 
call this symptom complex, researchers have also been unable 
to come to a consensus on a clinical definition of PMTS. 
However, even though there is no universally accepted defi-
nition of PMTS, a clear definition is necessary for the 
development of valid criteria for diagnosing the problem, 
grading its severity, and assessing responses to treatment 
(Abraham, 1983). Therefore, in order to grapple with this 
confusing disorder, and to maintain consistency and compara-
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bility with other studies, Abraham's definition of PMTS, 
which is as follows, will be used in this paper. 
PMTS is a symptom complex occurring during the 
luteal phase of the menstrual cycle, becoming pro-
gressively worse, interfering with familial, 
social and work-related activities and improving 
after the onset of menses. This definition 
implies that the symptoms are absent or mild dur-
ing the week after the end of menses and moderate 
or severe during the week before menses (Abraham, 
1983, p. 447). 
Incidence of PMTS 
PMTS research is hampered not only by the lack of a 
clear definition of PMTS, but also by the lack of specific 
inclusion-exclusion criteria, and the lack of a diagnostic 
test to determine the presence of PMTS. As a result, it is 
nearly impossible to determine how many women suffer with 
PMTS. If statistics are based on mild mood changes associ-
ated with the menstrual cycle, then nearly every menstruat-
ing woman has PMTS. Indeed, O'Brien (1982) indicated the 
incidence of PMTS had been reported to be as high as 95 per-
cent. However, if criteria are based on more severe symp-
toms or on the number of women seeking help, the numbers are 
much lower. Norris and Sullivan (1983) indicated only 10-15 
percent of menstruating women experience symptoms that dis-
rupt their lives. 
The incidence of PMTS is said to increase with age, 
parity, a history of pre-eclampsia, exposure to stress, when 
living with a male, and as a result of a lack of exercise 
(Abraham, 1980). Smith (1976) suggested PMTS occurs less 
3 
often in schizophrenics and women taking oral contracep-
tives. However, once again, estimates of the incidence of 
PMTS will vary depending on inclusion-exclusion criteria and 
the source of the sample studied. 
Symptoms of PMTS 
Symptoms associated with the menstrual cycle have been 
alluded to for eons. The symptoms of PMTS will generally 
occur 7 to 14 days prior to the onset of menses. The onset 
of symptoms will vary among women, but it will usually occur 
at the same time in the cycle of any one woman. 
There is a long list of symptoms of PMTS that encom-
passes almost every medical specialty. The most common 
psychological symptom of PMTS is tension, which is why this 
disorder is called premenstrual tension syndromes. One of 
the most common physical symptoms experienced is edema, 
which manifests itself in swollen ankles, a puffy face, or 
enlarged, tender breasts. Following are some of the most 
common symptoms of PMTS: 
1. Tension, anxiety 
2. Irritability, anger, aggression, hostility 
3. Mood swings, crying spells, sadness 
4. Swelling of extremities, bloating, weight gain 
5. Fatigue, lethargy, insomnia 
6. Headache, breast tenderness, jointjmuscle pain 
7. Decreased concentration, indecision, paranoia 
8. Nausea, diarrhea, constipation 
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9. Anorexia, compulsive eating, increased thirst 
10. Acne, recurrence of herpes infection 
11. Clumsiness, dizziness, seizures 
12. Changes in libido, heat flashes 
13. Decreased motivation, social isolation, poor impulse 
control. 
Clare (1983) and Koeske (1983) have suggested that 
symptoms of PMTS may be the result of interactions among 
biological, psychological, social, cultural, and environmen-
tal stress factors. Others have found evidence that indi-
cate a woman's negative expectations and attitudes about 
menstruation have an affect on how they view their PMTS 
symptoms (Ruble, 1977; Brooks, Ruble and Clark, 1977; Koeske 
and Koeske, 1975). 
Possible Causes of PMTS 
What causes some women~ but not others, to have premen-
strual problems? A plethora of theories regarding the pos-
sible causes of PMTS have been postulated since Frank (1931) 
first identified the symptom complex. However, because re-
searchers are operating without a standard definition of 
PMTS and without a diagnostic test to determine the presence 
of PMTS, no theory can be regarded as more than an hypothe-
sis (Ruble and Brooks-Gunn, 1979). 
Nevertheless, researchers have provided a variety of 
theories regarding the etiology of PMTS. The most popular 
theories point to the gonadal hormones, progesterone and 
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estrogen, as the cause of PMTS. Rubinow and Roy-Byrne 
(1984) found a great deal of conflicting data regarding 
altered gonadal steroid activity and suggested much of the 
diversity could be attributed to methodological flaws, such 
as failure to carefully define the syndrome, formulate a set 
of answerable questions, and select an homogeneous popu-
lation. 
Endocrine anomalies are almost universally implicated 
as the cause of PMTS, and aldosterone and prolactin have 
also been theorized as possible causes of PMTS. However, 
the aforementioned problems with study design continue to 
produce conflicting results and necessitate further investi-
gation before the relationship between these hormones and 
PMTS can be determined. 
Numerous nonhormonal theories have also been offered as 
possible causes of PMTS, including, nutritional deficien-
cies, prostaglandins, hypoglycemia, essential fatty acid 
metabolism abnormalities, disturbances in neuroendocrine 
function, allergies, altered brain activity, and numerous 
psychological hypotheses. None of these theories has been 
substantiated, and it is unlikely any single cause is 
responsible for the myriad of symptoms associated with PMTS, 
as Reid and Yen (1981) concluded when they described PMTS as 
a multifactorial neuroendocrine disorder. Until the 
methodological flaws pointed out by Rubinow and Roy-Byrne 
(1984) are corrected, the exact causes of PMTS will remain 
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uncertain and results of PMTS studies involving possible 
causes will continue to be contradictory. 
Treatments for PMTS 
Treatments for PMTS are as varied as theories about its 
etiology and range from self-help measures to hysterectomy. 
Henriksen (1961) did a survey of PMTS literature and found 
327 items being promoted as specific or adjuvant therapy for 
PMTS. A survey of physicians who had requested information 
from the PMS Action Committee revealed that the most com-
monly recommended treatments for PMTS were diet, exercise, 
vitamins, and progesterone. The least available and least 
recommended treatments were antiprostaglandins, bromocrip-
tine, and support groups for patients and their families 
(Lyon and Lyon, 1984). The efficacy of the numerous pharma-
cologic and nonpharmacologic treatments for PMTS is based 
largely on anecdotal evidence as a result of the consistent 
failure to investigate the proposed treatments with placebo-
controlled, double-blind studies. This is especially criti-
cal in studies involving PMTS due to the high placebo 
response rate of 30%-80% in patients with PMTS (Smith and 
Youngkin, 1986). 
The focus of this paper will be on the effectiveness of 
a pharmacologic treatment in the reduction of PMTS symptoms. 
According to True et al. (1985), of the many pharmacologic 
treatments that have been proposed, none has been shown to 
be reliably effective. This is the result of the studies of 
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PMTS treatment modalities being compromised by the same 
methodological flaws that hamper research into the cause of 
PMTS. The unknown etiology, the unclear definition, and the 
lack of objective parameters to measure complicates the dis-
covery of an effective PMTS treatment. Also, most studies 
have been conducted with small, heterogeneous samples and 
have consistently failed to design studies incorporating 
placebo-control groups. 
Statement of the Problem 
This study investigated the effect of an over-the-
counter (OTC) preparation consisting of 500 mg. of 
acetaminophen, 25 mg. of pamabrom, and 15 mg. of pyrilamine 
maleate in the relief of PMTS symptoms in women who met the 
established criteria for PMTS. 
Hypotheses 
1. There will be no significant difference in the scores 
for all PMTS symptoms when the pre-test menstrual symp-
tom questionnaire (MSQ) score is compared to the subse-
quent MSQ scores obtained after the active treatment 
and placebo has been administered. 
2. There will be no significant difference in the scores 
for specific PMTS symptoms found in the four PMTS sub-
groups Abraham (1983) has defined when the pre-test MSQ 
scores for the four PMTS subgroups are compared to the 
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subsequent MSQ scores obtained after the active treat-
ment and placebo has been applied. 
3. There will be no significant difference in the scores 
for all PMTS symptoms when comparing the active treat-
ment to the placebo. 
4. There will be no significant difference in the scores 
for the specific PMTS symptoms found in the four PMTS 
subgroups when comparing the active treatment to the 
placebo. 
5. There will be no significant difference in the scores 
for PMTS symptoms between the group on the birth 
control pill and the group not on the birth control 
pill. 
Limitations of the Study 
1. The MSQ was not constructed using standardized psycho-
metric procedures that would ensure internal consis-
tency, reliability, reduction of redundancy, and cohe-
siveness of subgroups (Rubinow and Roy-Byrne, 1984). 
2. The MSQ is not a diagnostic test which measures objec-
tive parameters, but rather relies on subjective 
reporting of symptoms. 
3. There is no universally accepted definition of PMTS. 
4. The symptoms of PMTS are widely variable and may not 
appear every cycle. 
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6. The type of birth control pill used by subjects was not 
identified. 
Delimitations of the Study 
1. The study was limited to an investigation of an OTC 
drug containing 500 mg. of acetaminophen, 25 mg. of 
pamabrom, and 15 mg. of pyrilamine maleate. 
2. The symptoms of PMTS were measured using a MSQ devel-
oped by Abraham (1983). 
3. Only subjects who indicated moderate or severe PMTS 
during the week before menses or mild or absent PMTS 
during the week after menses, according to their score 
on the pre-test MSQ, were included in the study. 
4. The subjects were limited to 58 women who were menstru-
ating regularly, did not suffer from regular headaches, 
and were not currently being treated for menstrual dis-
tress. 
5. The study was conducted over two consecutive menstrual 
cycles with the active treatment and placebo adminis-
tered in a double-blind fashion and PMTS symptoms 
recorded on the MSQ after each treated cycle. 
Assumptions 
1. It is assumed that the protocol for the ingestion of 
the treatments and subsequent evaluation of symptoms 
was maintained. 
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2. It is assumed that even though PMTS has no accepted 
clinical definition, nor an objective diagnostic t~st, 
the MSQ is an effective and acceptable measurement 
instrument for the presence and severity of PMTS symp-
toms. 
Definition of Terms 
Conceptual 
Syndrome. A set or constellation of symptoms or signs 
that together characterize or identify a specific disease or 
disorder. 
Premenstrual Tension syndrome (PMTS). A symptom com-
plex occurring during the luteal phase of the menstrual 
cycle, becoming progressively worse, interfering with famil-
ial, social and work-related activities and improving after 
the onset of menses (Abraham, 1983). 
Placebo. A medically inert substance formulated to 
mimic, in color and form, an active substance. 
over-the-counter COTC> Drug. A drug that the Federal 
Drug Administration (FDA) accepts as safe for self-medica-
tion. An OTC drug can be used by consumers for disorders 
they diagnose themselves and treat by following the direc-
tions on the label without advice from a physician. 
Analgesic. A drug like aspirin or acetaminophen that 
decreases pain. 
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Antihistamine. A drug like pyrilamine maleate used to 
treat an allergy by counteracting the effects of histamine, 
which is manufactured by certain cells in the body. 
Diuretic. A drug like pamabrom that tends to decrease 
the amount of fluid retention. 
Functional 
Premenstrual Tension-Anxiety (PMT-A). This subgroup is 
representative of those women who experience anxiety, irri-
tability and nervous tension (Abraham, 1983). 
Premenstrual Tension-Hydration (PMT-H). This subgroup 
is associated with symptoms of water and salt retention, 
abdominal bloating, mastalgia and weight gain (Abraham, 
1983) . 
Premenstrual Tension-Carbohydrates (PMT-C). This sub-
group is characterized by craving for sweets, increased 
appetite and indulgence in eating refined sugar followed by 
palpitation, fatigue, fainting spells, headache and some-
times the shakes (Abraham, 1983). 
Premenstrual Tension-Depression (PMT-D). This subgroup 
is potentially the most dangerous because symptoms include 
depression, withdrawal, confusion, insomnia and forgetful-
ness (Abraham, 1983). 
Mild PMTS. The score on the Menstrual Symptom 
Questionnaire (MSQ) is less than five for PMT-A and PMT-H, 
less than six for PMT-D and less than seven for PMT-C 
(Abraham, 1983) . 
12 
Moderate PMTS. The score on the MSQ is between five 
and eight for PMT-A and PMT-H; between six and ten for PMT-
D; and between seven and twelve for PMT-C (Abraham, 1983). 
Severe PMTS. The score on the MSQ is between nine and 
twelve for PMT-A and PMT-H; between eleven and fifteen for 
PMT-D; and between thirteen and eighteen for PMT-C (Abraham, 
1983). 
Description of Instrument 
The Menstrual-Symptom Questionnaire (MSQ) utilized in 
this study is a retrospective questionnaire developed by 
Abraham (1980). The MSQ consists of nineteen symptoms 
arranged into four subgroups. The MSQ is used as a 
screening tool to detect the presence and severity of PMTS 
and then used after the treatment is applied to evaluate any 
symptom changes that may have occurred as a result of the 
treatment (see Appendix). 
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CHAPTER II 
A SELECTED REVIEW OF LITERATURE 
The Food and Drug Administration (FDA) Advisory Review 
Panel on Over-the-Counter (OTC) Miscellaneous Internal Drug 
Products (hereinafter referred to as Miscellaneous Internal 
Panel) reviewed 73 active ingredients for relieving symptoms 
of PMTS and menstrual distress. Ten of the ingredients were 
classified as Category I, 58 ingredients as category II, and 
six ingredients as Category III (Fed. Reg., 1982). Cate-
gory I means conditions under which OTC menstrual drug prod-
ucts are generally recognized as safe and effective and are 
not misbranded. category II means conditions under which 
OTC menstrual drug products are not generally recognized as 
safe and effective or are misbranded. Category III means 
conditions for which the available data are insufficient to 
permit final classification at this time (Fed. Reg., 1982). 
The product under investigation in this study, a combi-
nation of an analgesic, acetaminophen; a diuretic, pamabrom, 
and an antihistamine, pyrilamine maleate, was classified as 
category I because the individual ingredients were classi-
fied as Category I. The present classification of these 
ingredients as a treatment for PMTS has only appeared in an 
Advanced Notice of Proposed Rulemaking (Fed. Reg., 1982), 
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which is the first stage in the FDA's three stage approval 
process for OTC drugs. This means that the FDA has not_yet 
fully evaluated the report by the Miscellaneous Internal 
Panel. At this stage of the approval process, the panel's 
findings were issued to generate public comment before the 
FDA made any decision on the Miscellaneous Internal Panel's 
recommendation (Fed. Reg., 1982). So, even though the prod-
uct has gained initial approval, the FDA will continue to 
evaluate results of studies involving these products before 
making a final determination. 
Pamabrom 
The use of diuretics for PMTS was based on the observed 
retention of water and electrolytes in so many women who ex-
perienced premenstrual distress. According to Velacott and 
O'Brien (1987), PMTS has long been considered a disorder in 
which fluid retention plays a major role. However, the role 
of diuretics as a PMTS treatment is still unsettled as 
investigations into the efficacy of diuretics in the treat-
ment of PMTS have produced widely variable results. Never-
theless, numerous etiologic theories and treatment protocols 
are based on this premise. 
The diuretic under investigation in this study, pam-
abrom, a xanthine derivative, was approved for OTC marketing 
in 1952 as a single entity diuretic and in combination with 
pyrilamine maleate, an antihistamine. More recently, the 
Miscellaneous Internal Panel reviewed two studies by 
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Hutcheon (1977, 1981) and a study called the Wisconsin Study 
(1978). The Miscellaneous Internal Panel considered one 
Hutcheon Study (1981) and the Wisconsin study (1978) to be 
only suggestive of the effectiveness of pamabrom as a 
diuretic, but based upon the results of the earlier Hutcheon 
study (1977) the panel concluded that pamabrom was generally 
recognized as a safe and effective diuretic in removing the 
symptoms associated with water accumulation during the pre-
menstrual period (Fed. Reg., 1982). 
Despite the widely variable results obtained from stud-
ies involving diuretic therapy for PMTS and despite the fact 
that the underlying fluid retention theory remains in doubt, 
diuretics appear to have a role in the management of PMTS. 
According to the Miscellaneous Internal Panel, the only 
proper use of OTC diuretics is in eliminating water accumu-
lation during the premenstrual and menstrual periods, which 
relieves the symptoms of water weight gain, bloating, 
swelling, andjor a full feeling (Fed. Reg., 1982). The safe 
use of OTC diuretics for PMTS is based on the fact these 
conditions are self-diagnosable, limited in duration, occur 
intermittently, and are not symptoms of a potentially seri-
ous underlying disorder (Fed. Reg., 1982). 
Pyrilamine Maleate 
The rationale for using pyrilamine maleate as a treat-
ment for PMTS is based on a theory that was reported in the 
Wisconsin Study (1978) that suggested the PMTS sufferer is 
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allergic to her own steroids. A study based on this afore-
mentioned theory also reported in the Wisconsin Study (~978) 
demonstrated that the amount of histamine in the body 
increases and decreases with fluctuations in estrogen levels 
during the menstrual cycle. These theories provide the 
basis for the hypothesis that the administration of an anti-
histamine, like pyrilamine maleate, could prevent or relieve 
vascular congestion caused by abnormal water retention. 
Other studies involving pyrilamine maleate demonstrated 
local anesthetic activity (Dews and Graham, 1946; Haranath, 
1954) and found that pyrilamine maleate exerted a mild anal-
gesic action (Hewer and Keele, 1948). 
More recent studies performed to document the effect of 
pyrilamine maleate on symptoms of PMTS were submitted by 
Chattem Inc. to the FDA & Advisory Review Panel on OTC Mis-
cellaneous Internal Drug Products. In the Wisconsin Study 
(1978) 194 women participated in a placebo-controlled, 
double-blind, single cross-over design study to assess the 
effects of pyrilamine maleate and pamabrom on the symptoms 
of PMTS when administered separately and in a fixed combina-
tion. The results of the study indicated that pyrilamine 
maleate significantly reduced the symptoms of tension, irri-
tability and cramps. The Boston Study (1981) confirmed the 
findings of the Wisconsin Study (1978) and expanded the 
effect of pyrilamine maleate on the reduction of the inten-
sity of symptoms associated with PMTS by including backache 
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and swelling in the list of symptoms improved by pyrilamine 
maleate. 
Even though the Miscellaneous Internal Panel recom-
mended that pyrilamine maleate be classified as category I 
"for the relief of emotional changes related to the premen-
strual period" and "for relief of water retention symptoms," 
the FDA was concerned that the data that were reviewed were 
too conflicting and may not be sufficient to provide general 
recognition of effectiveness (Fed. Reg., 1982). As a conse-
quence, the FDA suggested that products containing pyril-
amine maleate as a single ingredient and being promoted as a 
treatment for PMTS should not be marketed at this time. 
Acetaminophen 
The Miscellaneous Internal Panel has also reviewed sub-
missions proposing the use of acetaminophen for the treat-
ment of PMTS. The Miscellaneous Internal Panel concluded 
that acetaminophen was generally recognized as safe and 
effective for OTC use in relieving pain of the premenstrual 
syndrome (Fed. Reg., 1982). 
The Miscellaneous Internal Panel came to this conclu-
sion based on information provided by the Advisory Review 
Panel on OTC Internal Analgesic and Antirheumatic Drug Prod-
ucts (hereinafter referred to as the Internal Analgesic 
Panel). The Internal Analgesic Panel concluded that OTC 
analgesic drugs are intended to alleviate the symptoms of 
mild to moderate pain, specifically the type of pain that is 
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self-limiting and requires no special treatment or prior 
diagnosis by a physician (Fed. Reg., 1977). The Miscella-
neous Internal Panel considered pain associated with PMTS to 
be in that category and concluded that any analgesic that 
had been given a Category I designation by the Internal 
Analgesic Panel for a label claim of "For the temporary 
relief of occasional minor aches, pain, and headaches" (Fed. 
Reg., 1977, pp. 35351) may be used with a label claim relat-
ing to the relief of pain associated with PMTS (Fed. Reg., 
1982) • 
Combination Products 
Studies have been done involving acetaminophen, pam-
abrom, and pyrilamine maleate individually, but no studies 
have been done involving a preparation consisting of these 
three ingredients in combination. The FDA allowed products 
containing 500 mg. acetaminophen, '25 mg. pamabrom, and 15 g. 
pyrilamine maleate to be marketed based on the conclusion of 
the Miscellaneous Internal Panel that the addition of any 
Category I analgesic to a diuretic/antihistamine combination 
would result in a category I classification because all of 
the individual ingredients had a category I designation. 
Despite the fact that this combination of 
acetaminophen, pamabrom, and pyrilamine maleate has been 
classified as category I for the treatment of PMTS, there is 
still a great deal of uncertainty regarding their use and 
effectiveness. One complicating factor in the therapeutic 
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management of PMTS is that PMTS responds to almost anything, 
including placebos, at least for a while (Hopson and Rosen-
feld, 1984). As a result, claims are often made that cer-
tain drugs for PMTS alleviate all symptoms and cure all 
patients. To date, most prescription drugs and OTC medica-
tions have not proven to be any more effective than placebo 
in combating symptoms of PMTS (Switzer, 1983). It appears 
no one drug or behavioral therapy offers relief to all 
because PMTS manifests itself through so many symptoms that 
it makes a universal treatment approach unrealistic. 
Based on the conflicting reports concerning PMTS treat-
ments, clinicians have taken two approaches to therapy 
according to O'Brien (1982). The first approach is one drug 
cures all. For instance, progesterone has often been pro-
moted as a "cure" for PMTS. The second approach involves 
the administration of various drugs in a random fashion 
based on the therapist's clinical experience with the drugs, 
otherwise known as a shot gun approach. For example Chak-
makjian (1983) suggested the following treatment regimen for 
PMTS. First, the patient and her family should be counseled 
and given support. Recognition of the condition as physio-
logic could aid the patient in coping with the symptoms. 
Second, for patients with moderate to severe symptoms, the 
use of vitamin B6 or a multivitamin mineral formulation 
(Optivite) designed specifically for PMTS may provide some 
benefit. Third, patients who complain primarily of irri-
tability can use progesterone suppositories. For patients 
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who complain primarily of depression, small doses of estro-
gen can be given during the luteal phase of the menstrual 
cycle. Fourth, when mastalgia is the primary complaint, 
bromocriptine may provide relief. Finally, when edema is 
present, diuretic therapy is beneficial. 
Caught in the middle of this treatment dilemma is the 
PMTS sufferer. According to Keye (1985), medical treatments 
for PMTS can be divided into three major groups. The first 
group includes treatments that are designed to relieve spe-
cific symptoms without attempting to modify the underlying 
disease process. The next group consists of treatments that 
presumably correct what is hypothesized as the underlying 
pathophysiology of the disorder. The last group contains 
treatments that alter the normal ovulatory menstrual cycle. 
The product under investigation in this study falls into the 
first treatment category. 
The purpose of this study is to determine the effec-
tiveness of an analgesic, diuretic, antihistamine combina-
tion in the treatment of PMTS. At the present time there is 
no clear cut evidence for the effectiveness of any one 
treatment (Keye, 1985). That is because previous investiga-
tions have been compromised by various factors. 
O'Brien (1835) suggested many factors that may impact 
PMTS studies such as, an inexact definition of PMTS, no 
objective parameters to measure in order to make a correct 
diagnosis, and the unknown cause of the disorder. However, 
the primary cause of the abundance of inadequate PMTS 
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research is the consistent failure to use placebos in drug 
trials when the high placebo response rate in PMTS {30%-80%) 
requires the inclusion of a placebo-control group {Smith and 
Youngkin, 1986). According to Steiner and Carroll {1977), 
most controlled studies report favorable results, whereas 
most placebo controlled studies fail to demonstrate 
drug/placebo differences or find placebo to be the superior 
treatment. 
Other factors that influence research results are small 
sample sizes, studies too short in duration to validate the 
effectiveness of the treatment, an heterogeneous sample, and 
poor control over concomitant medications (Chakmakjian, 
1983; and Harrison et al., 1985). 
In the Handbook of Nonprescription Drugs {1982) it is 
stated that OTC drugs are intended to be used to treat symp-
toms of minor discomfort, illness or injury. The FDA has 
been involved since 1972 in a review of nonprescription drug 
products to ensure that they contain safe and effective 
ingredients and bear fully informative labeling. However, 
for most nonprescription drugs there need not be an affirma-
tive demonstration that specific formulations of active and 
inactive ingredients are safe and effective (Handbook of 
Nonprescription Drugs, 1982). This is one of the many rea-
sons that compelled this author to investigate the effec-
tiveness of PMTS treatments more fully. 
Other reasons that stimulated an interest in this area 
of research include: 
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1. Drug companies which manufacture PMTS products were 
supplying the Miscellaneous Internal Panel with results 
of in-house studies. 
2. The Miscellaneous Internal Panel's report was designed 
to generate public comment. 
3. There is no clear indication which drug should be given 
to treat this condition. 
4. A drug company's promotion of a product that has yet to 
be proven effective is exploitative,and is taking 
advantage of women in a fragile condition, many of whom 
are afflicted with chemophilia, an attitude generated 
from drug company promotion of "a pill for every ill." 
It is the hypothesis of this author that the active 
treatment in this study, which consists of 500 mg. 
acetaminophen, 25 mg. pamabrom, and 15 mg. pyrilamine 
maleate, is not effective in the treatment of PMTS, and at 
the very most, no more effective than a placebo. 
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CHAPTER III 
METHODS AND PROCEDURES 
This study investigated the effects of an over-the 
counter (OTC) product containing 500 mg. of acetaminophen, 
an analgesic; 25 mg. of pamabrom, a diuretic; and 15 mg. of 
pyrilamine maleate, an antihistamine, on symptoms associated 
with premenstrual syndrome. Both the active treatment and 
the placebo were supplied by Glenbrook Laboratories, a Divi-
sion of Sterling Drug Inc. The methods and procedures were 
submitted to and approved by the Oklahoma State University 
Institutional Review Board. 
A total of 58 females initially agreed to participate 
in this double-blind, cross-over design study which lasted 
two months. The subjects were required to orally ingest 
eight caplets per day of either the active treatment or 
placebo when the symptoms of PMTS first presented themselves 
or when the subjects could expect the symptoms with some 
certainty, and continue this regimen until the beginning of 
menses. The subjects completed a menstrual symptom 
questionnaire (MSQ) at the beginning, at cross-over, and at 
the conclusion of the study. Standardized statistical 
methods were used for analyses. 
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Selection of Subjects 
The population for this study was menstruating women 
who experienced premenstrual discomfort. A convenience sam-
ple of 58 women was obtained as a result of women responding 
to newspaper ads in the local paper and announcements on 
numerous bulletin boards throughout the Stillwater community 
and the Oklahoma State University campus. Subjects were 
also recruited from a number of health classes at Oklahoma 
State University. Forty-four of the subjects actually pro-
duced data. Of those who dropped out of the study, eight of 
the subjects did not have severe enough symptoms to warrant 
treatment, five subjects moved out of town and out of touch, 
and one subject got pregnant. 
In order to be selected for the study the subjects had 
to have documented PMTS based on the criteria established by 
Abraham (1980) for women who scored their symptoms using a 
menstrual symptom questionnaire (MSQ). Subjects with moder-
ate or severe symptoms of PMTS according to their score on 
the MSQ were asked to participate in the study. Those who 
agreed were randomly assigned to one of two groups. One 
group received the placebo first and then crossed over to 
the active treatment while the second group received the 
active treatment first then crossed over to the placebo. 
The ages of the subjects ranged from 17-42 years (mean 
26.8). The weight of the subjects ranged from 90-228 pounds 
(mean 130.27). The number of pregnancies previously 
experienced by the subjects ranged from 0-3 (mean .66). The 
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length of the subjects menstrual cycles ranged from 20-34 
days (mean 28.1). Twenty-four of the subjects were taking 
oral contraceptives while 20 were not taking the birth 
control pill. 
Personal Data 
Upon making contact with the investigator each subject 
was initially required to read and sign an informed consent 
for the testing procedure (see Appendix). Then each subject 
filled out an MSQ consisting of a brief personal history 
which included questions regarding age, height, weight, 
marital status, present contraception, previous treatment 
for PMTS, and length of menstrual cycle (see Appendix). 
Also included on the form was a premenstrual symptom 
rating scale which yielded the baseline data that was used 
to screen subjects for participation in the study. Each 
subject was asked to evaluate her premenstrual symptoms for 
her last menstrual cycle. All subjects were also asked to 
grade the effects of PMTS on marital, familial, social and 
work-related activities during their last menstrual cycle 
(see Appendix). The forms were thoroughly explained by the 
investigator and questions were answered to the satisfaction 
of each of the subjects. 
Data Collection 
After completing the informed consent and the initial 
MSQ and agreeing to participate in the study, all of the 
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subjects were given instructions regarding the treatment 
protocol they were to follow for their next two menstrual 
cycles. For both of the test periods all of the subjects 
were asked to take eight caplets per day of whatever treat-
ment they were receiving that month when symptoms of PMTS 
were present. 
After completion of the treatment all of the subjects 
were asked to fill out a new premenstrual symptom rating 
scale. In addition, the subjects were asked if they fol-
lowed the dosage recommendations and if there were any side 
effects while on the treatment. The same protocol was used 
for both test periods. 
Instrumentation 
The instrument used in this study to measure the pres-
ence of PMTS and the effect of the treatment on the symptoms 
of PMTS was a MSQ developed by Abraham (1980) (see Appen-
dix). This MSQ was a modified form of a menstrual distress 
questionnaire developed by Moos (1968) and consisted of 19 
items arranged into four subgroups. The four subgroups 
included: PMT-A, consisting of nervous tension, mood 
swings, irritability and anxiety; PMT-H, which included 
weight gain, swelling, breast tenderness and abdominal 
bloating; PMT-C, consisting of headache, craving for sweets, 
increased appetite, heart pounding, fatigue and dizziness; 
and PMT-D, which included depression, forgetfulness, crying, 
confusion and insomnia. 
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The symptoms were evaluated on a four-point scale which 
consisted of: 0 = none; 1 = mild - present but does not 
interfere with activities; 2 = moderate - present and inter-
feres with familial, marital, social and work-related activ-
ities but is not disabling; and 3 = severe - disabling with 
marked decrease in performance and inability to function. 
Statistical Treatment 
This study was placebo-controlled, double-blind, and 
employed a cross-over research design. In this design each 
subject was allowed to act as her own control (Campbell and 
Stanley, 1963). 
The data were analyzed using a 3 x 2 repeated measures 
analysis of variance with a trial factor at three levels 
(pre-test vs. active vs. placebo), and a grouping factor at 
two levels (birth control pill vs. no birth control pill). 
The following dependent variables were each analyzed sepa-
rately: (1) total MSQ score; (2) PMT-A score; (3) PMT-H 
score; (4) PMT-C score; and (5) PMT-D score. All statisti-
cal tests were performed using the .05 level of signifi-
cance. statistical analysis was done through the Oklahoma 
State University Computer Center. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
The purpose of this study was to determine if an over-
the-counter (OTC) product consisting of 500 mg. of 
acetaminophen, 25 mg. of pamabrom and 15 mg. of pyrilamine 
maleate ameliorated the symptoms of PMTS in 44 subjects with 
documented PMTS according to their score on a menstrual 
symptom questionnaire (MSQ). The experimental design was a 
double-blind cross-over utilizing two groups, with each sub-
ject acting as their own control. The groups were con-
trolled by administering a placebo. 
All of the 44 subjects had documented the presence of 
their PMTS symptoms by completing a MSQ. All of the sub-
jects rated their symptoms on the pre-test MSQ as moderate 
or severe according to the criteria established by Abraham 
(1980). At the time of the study none of the subjects were 
taking any other treatments for PMTS or any other OTC medi-
cations. No other attempts were made to control the general 
living habits of the subjects, except in the days immedi-
ately preceding menses, when late, irregular hours and alco-
hol were to be avoided in so far as possible. 
Of the 58 subjects that began the study, 44 completed 
the study. Eight of the subjects did not have severe enough 
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symptoms to justify treatment, five of the subjects moved 
and dropped out of the study, and one became pregnant and 
dropped out of the study. Both the active treatment and the 
placebo were tolerated well by all subjects with the excep-
tion of three subjects who experienced side effects while on 
the active treatment. One subject reported lowered blood 
pressure and light headedness, one said she became groggy 
and thirsty, and one said she became very irritable and 
tired. 
Results 
The means and standard deviations by group (birth con-
trol pill vs. no birth control pill) and by condition (pre-
test vs. active treatment vs. placebo) for the dependent 
variable of total MSQ score are given in Table I. The means 
and standard deviations by group and by condition for the 
other four dependent variables (PMT-A, PMT-H, PMT-C, PMT-D) 
are given in Tables II-V. 
Results of Total MSO Score Analysis 
The results of the total MSQ score analysis by group 
and by condition are given in Table VI. There was a change 
in the total MSQ score at the .01 level of significance. A 
Newman-Keuls post hoc analysis was performed to determine 
the nature of the difference and a statistically significant 
difference was revealed between the pre-test MSQ score and 
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Pretest 
Active 
Placebo 
TABLE I 
MEANS AND STANDARD DEVIATIONS FOR 
TOTAL MSQ SCORE 
Birth Control No Birth 
Pill Control Pill 
22.55 ± 6.95 26.29* ± 7.70 
24.75 ± 9.37 23.42 ± 11.58 
23.95 ± 10.39 20.25* ± 11.07 
* 26.29 significantly different from 20.25 
Pretest 
Active 
Placebo 
* 
7.59 
TABLE II 
MEANS AND STANDARD DEVIATIONS FOR 
PMT-A MSQ SCORE 
Birth Control No Birth 
Pill Control Pill 
7.20 + 2.19 7.92 ± 2.17 
7.15 ± 2.58 6.88 ± 2.88 
6.90 ± 2.45 6.00 ± 3.04 
significantly different from 6.41 
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All 
Subjects 
24.59 
24.02 
21.93 
All 
Subjects 
7.59* 
7.00 
6.41* 
Pretest 
Active 
Placebo 
Pre-test 
Active 
Placebo 
TABLE III 
MEANS AND STANDARD DEVIATIONS FOR 
PMT-H MSQ SCORE 
Birth Control No Birth 
Pill Control Pill 
4.90 + 2.29 6.21 ± 2.40 
5.80 ± 3.07 5.54 + 2.78 
5.55 ± 2.67 4.71 ± 3.16 
TABLE IV 
MEANS AND STANDARD DEVIATIONS FOR 
PMT-C MSQ SCORE 
Birth Control No Birth 
Pill Control Pill 
5.70 ± 2.49 6.88 ± 3.662 
6.35 ± 2.70 5.92 + 3.67 
6.10 + 3.74 5.38 ± 3.81 
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All 
Subjects 
5.61 
5.66 
5.09 
All 
Subjects 
6.34 
6.11 
5.70 
Pre-test 
Active 
Placebo 
Source 
Pill group 
Error 
Condition 
Condition x 
pill group 
Error 
* P<.01 
TABLE V 
MEANS AND STANDARD DEVIATIONS FOR 
PMT-D MSQ SCORE 
Birth Control No Birth 
Pill Control Pill 
4.75 ± 2.85 5.29 ± 2.94 
5.50 + 2.91 5.04 ± 4.12 
5.40 + 3.44 4.17 ± 3.63 
TABLE VI 
ANALYSIS OF VARIANCE FOR 
TOTAL MSQ SCORE 
ss d. f. M.S. 
6.07 1 6.07 
9290.90 42 221.21 
137.22 2 68.61 
315.40 2 157.70 
2612.04 84 31.10 
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All 
Subjects 
5.05 
5.25 
4.73 
F* 
0.03 
2.21 
5.07 
the MSQ score obtained after the subjects took the placebo 
for the group of women not taking the birth control pill. 
Results of MSQ Score Analysis 
for PMT-A Subgroup 
The results of the MSQ score analysis for the PMT-A 
subgroup by group and by condition are given in Table VII. 
There was a change in the PMT-A score at the .05 level of 
significance. A subsequent Newman-Keuls post hoc analysis 
revealed a statistically significant difference between the 
pre-test MSQ score and the MSQ score after the placebo was 
taken when the scores of both groups were combined. 
Results of MSQ Score Analysis 
for PMT-H Subgroup 
The results of the MSQ score analysis for the PMT-H 
subgroup by group and by condition·are given in Table VIII. 
There was a change in the PMT-H score at the .05 level of 
significance for the group of women who were not taking the 
birth control pill. However, a Newman-Keuls showed no pairs 
of means to be significantly different from one another. 
Results of MSQ Score Analysis 
for PMT-C Subgroup 
The results of the MSQ score analysis for the PMT-C 
subgroup by group and by condition are given in Table IX. 
There was a change in the PMT-C score at the .05 level of 
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Source 
Pill group 
Error 
Condition 
Condition x 
pill group 
Error 
* P<.Ol 
Source 
Pill group 
Error 
Condition 
Condition X 
pill group 
Error 
* P<.05 
TABLE VII 
ANALYSIS OF VARIANCE FOR 
PMT-A MSQ SCORE 
ss d. f. M.S. 
0.76 1 0.76 
547.90 42 13.05 
26.80 2 13.40 
14.50 2 7.25 
294.11 84 3.50 
TABLE VIII 
ANALYSIS OF VARIANCE FOR 
PMT-H. MSQ SCORE 
ss d. f. M.S. 
0.1666 1 0.16 
685.90 42 16.33 
7.09 2 3.55 
26.97 2 13.49 
266.92 84 3.18 
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F* 
0.006 
3.83 
2.07 
F* 
0.01 
1.12 
4.24 
Source 
Pill group 
Error 
Condtion 
Conditoin X 
pill group 
Error 
* P<.05 
TABLE IX 
ANALYSIS OF VARIANCE FOR 
PMT-C MSQ SCORE 
ss d. f. M.S. 
0.001 1 0.001 
1171.961 42 27.904 
7.025 2 3.512 
22.843 2 11.421 
294.672 84 3.508 
F* 
0.00 
1.00 
3.26 
significance for the group of women who were not taking the 
birth control pill, but a subsequent Newman-Keuls revealed 
no pairs of means to be significantly different from one 
another. 
Results of MSQ Score Analysis for 
PMT-D Subgroup 
The results of the MSQ score analysis for the PMT-D 
subgroup by group and by condition are given in Table X. 
There was no change in the PMT-D score at the .05 level of 
significance. 
36 
Source 
Pill group 
TABLE X 
ANALYSIS OF VARIANCE FOR 
PMT-D MSQ SCORE 
ss d. f. M.S. 
4.809 1 4.809 
Error 1189.517 42 28.322 
Condition 5.186 2 2.593 
Condition x 
pill group 17.277 2 8.638 
Error 243.283 84 2.896 
* No significance 
Discussion of Results 
F* 
0.17 
0.90 
2.98 
The interaction between the active treatment in this 
study and the symptoms of PMTS is not clearly understood at 
the present time. This is the first study to investigate 
acetaminophen, pamabrom, and pyrilamine maleate in combina-
tion. Previous studies have only investigated the effects 
of pamabrom and pyrilamine maleate individually and in com-
bination, and have produced conflicting results. In this 
study, even though statistically significant differences 
were seen in a couple of areas, the differences were so 
small that no practical beneficial outcome was derived. 
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The results of this study indicated statistically sig-
nificant changes in PMTS scores in four different areas. 
Three of the changes occurred in the group of women who were 
not taking oral contraceptives. For these women there was a 
reduction in their total MSQ score, the MSQ score for the 
PMT-H subgroup, and the MSQ score for the 
PMT-C subgroup. However, the reduction of their MSQ scores 
was not large enough to reflect any relief of symptoms of 
PMTS. In other words, the women in this study suffer from 
what has been described as moderate-to-severe PMTS according 
to their MSQ scores (Abraham 1980) and the observed 
reduction in the MSQ scores indicated the subjects still had 
noticeable symptoms. Also, it must be noted that all of the 
statistically significant changes in MSQ scores occurred 
between the pre-test and the placebo cycle. This is 
consistent with the extremely high placebo response rate, 
30%-80%, seen in studies of PMTS treatment (Smith and 
Youngkin 1986). 
The other statistically significant change seen in this 
study occurred between the pre-test and the placebo cycle 
for the PMT-A subgroup for both groups of subjects combined. 
Once again, even though the change in the MSQ score was sta-
tistically significant, no practical benefit was derived 
from the limited symptom reduction because the women still 
had noticeable symptoms of PMTS. 
It is difficult to compare the results of this study to 
other studies involving PMTS treatments for a number of rea-
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sons. First, no other study has been done using the parti-
cular combination investigated in this study, which consists 
of 500 mg. of acetaminophen, 25 mg. of pamabrom, and 15 mg. 
of pyrilamine maleate. Second, the instrument used to mea-
sure the presence and severity of PMTS varies from study to 
study. Finally, many of the past studies were open trials 
rather than placebo-controlled studies. 
The effectiveness of acetaminophen in the relief of 
premenstrual discomfort by itself or in combination with 
other products has not been determined because it has not 
been investigated for that particular purpose. Neverthe-
less, acetaminophen has been commonly used for menstrual 
pain in the past and has been rated as safe when taken in 
recommended doses (Federal Register 1977). 
The Wisconsin Study (1978) investigated the effects of 
50 mg. of pamabrom on symptoms of PMTS and found that it 
reduced the symptoms of headache, depression and finger 
swelling. In contrast, Rogers (1964) pointed out that 
diuretics frequently failed to relieve headache, tension and 
nervousness (in Wisconsin Study 1978). Harrison, Sharpe and 
Endicott (1985) reviewed five controlled studies of diuret-
ics and only two demonstrated a beneficial effect. It 
should also be mentioned that the blind nature of any trial 
using diuretics is questionable because the increased urina-
tion caused by the active treatment provides clues as to the 
nature of the treatment. 
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The Wisconsin Study (1978) also investigated the 
effects of 25 mg. of pyrilamine maleate on PMTS symptoms and 
discovered it reduced tension, irritability, and cramps. 
Another study by McColl and Durkin (1981) found pyrilamine 
maleate to be effective in reducing the intensity of cramps, 
backache, anxiety, and swelling. These are the only studies 
that have been done involving pyrilamine maleate by itself. 
The effect of 50 mg. of pamabrom and 25 mg. of pyril-
amine maleate in combination on symptoms of PMTS has also 
been investigated. It has been suggested that this combina-
tion produced an enhanced clinical response on breast ten-
derness, swelling of the abdomen, cramps, tension, swelling 
of the fingers and ankles, headache, depression, and irri-
tability (Wisconsin Study, 1978). 
Despite the differences in the selection of subjects, 
type of experimental treatment, and the type of instrument 
used to measure the presence and severity of PMTS, all of 
the aforementioned studies that indicated a reduction in 
symptoms of PMTS had something in common. Even though some 
reduction in symptoms of PMTS was observed, and those reduc-
tions were statistically significant, none of the studies 
revealed a reduction great enough to have any real practical 
benefit for women with PMTS. 
There are a number of complicating factors that make it 
difficult to interpret the results of this study and other 
studies involving the investigation of treatments for PMTS. 
One primary area of concern in PMTS research which has made 
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interpretation of results very difficult is the lack of an 
objective instrument for assessing the condition. Measure-
ment of body dimensions, blood changes, and weight have been 
found to be of no value in diagnosing and evaluating symp-
toms of PMTS and responses to therapy (O'Brien, Faratian, 
Gaspar et al., 1983). Self-assessment of mood is the most 
widely used method at present and may consist of a daily 
menstrual chart, the Moos MDQ {1968), or Abraham's MSQ 
(1980). According to O'Brien (1985), the menstrual chart is 
useful in assessing the character and timing of symptoms, 
but is of no benefit in assessing the severity of symptoms 
and consequently is only useful for diagnosis. The other 
two methods are more widely used in research because they 
reflect both the timing and the degree of disability. 
Both the Moos MDQ {1968) and the Abraham MSQ (1980) are 
retrospective questionnaires. It has been suggested by a 
number of researchers (McCance, Ruff and Widdowson, 1937; 
Ablanalp, Donnelly and Rose, 1978; Sampson and Prescott, 
1981) that retrospective symptom ratings are not generally 
validated by daily prospective ratings, but in fact, overes-
timate symptoms. A study by Endicott and Halbreich {1982) 
compared 48 women's retrospective reports of premenstrual 
depression with their rating of depression in their daily 
menstrual diary and found the women described the symptoms 
as much less severe in their daily reports than they did in 
their retrospective report. On the other hand, Moos {1968) 
and Rouse (1978) found that when a retrospectively adminis-
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tered questionnaire was completed by women at different 
phases of their most recent menstrual cycle, no phase effect 
on their symptom scores was obtained. 
Abraham's MSQ (1980) was utilized in this study and is 
a modified version of the Moos MDQ (1968). Rubinow and Roy-
Byrne (1984) evaluated both questionnaires and found both 
lacking in one way or another. The Moos MDQ (1968), a 47-
item checklist, focused largely on physical symptoms with 
the psychological, emotional, and behavioral symptoms being 
less extensively cataloged. The lack of specific inclusion 
and exclusion criteria limited the ability of the MDQ to 
translate changes in mood and behavior into useful diagnos-
tic categories (Rubinow and Roy-Byrne, 1984). Abraham's MSQ 
(1980) consists of a 19-item symptom checklist divided into 
four subgroups. Unfortunately, since the scale only con-
tained 19 items and was not constructed by using standard-
ized psychometric procedures which would ensure internal 
consistency, reliability, reduction of redundancy, and cohe-
siveness of subgroups, the sensitivity and specificity of 
this construct was seen as questionable (Rubinow and Roy-
Byrne, 1984). So, at the present time there is no univer-
sally accepted method of objectively evaluating syndromes 
that more frequently consist of internally experienced symp-
toms than objective behavioral signs, and consequently, 
interpretation of results is very difficult. 
A number of other factors which have been cited in the 
literature and make it difficult to meaningfully interpret 
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the results of this study are as follows: (1) the etiology 
of PMTS is no closer to being understood than when it was 
first described by Frank (1931), and there remains no con-
sistent data on the physiologic, biochemical and endocrine 
changes that occur during the premenstrual phase (O'Brien, 
1985); (2) PMTS has never been adequately defined, which has 
made it impossible to delineate specific parameters to mea-
sure to determine the presence and severity of PMTS; (3) 
there is considerable diversity in severity and variability 
of PMTS symptoms from patient-to-patient and in the same 
patient from month-to-month (Chakmakjian, 1983); (4) the 
placebo response rate has been chronicled as being between 
30%-80% in subjects with PMTS (Smith and Youngkin, 1986) and 
is partially the result of inadequate instruments for deter-
mining the presence and severity of PMTS symptoms; and (5) a 
lack of control over lifestyle variables such as diet, exer-
cise, stress, rest, and the use of drugs also makes it dif-
ficult to interpret these results. 
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CHAPTER V 
SUMMARY, FINDINGS, CONCLUSION 
AND RECOMMENDATIONS 
Summary 
Ever since Frank (1931) first described a group of 
symptoms occurring cyclically during the premenstruum, women 
suffering from what has come to be called PMTS, have been 
inundated by treatment options promoted by physicians and 
pharmaceutical companies. over 300 therapies have been pro-
moted for providing relief from the disruptive and at times 
disabling symptoms of PMTS, yet the effectiveness of these 
therapies has never been substantiated. 
In recent years PMTS has become a recognized clinical 
entity affecting a large portion of the female population. 
A reflection of the increasing concern about PMTS is the ex-
istence of more than 200 free-standing clinics and referral 
or information sources directed at PMTS sufferers within the 
United States (True, Goodner and Burns, 1985). However, 
women seeking advice or treatment for PMTS must be acutely 
aware of false claims and dubious schemes in the market-
place. OTC products which were once marketed to relieve 
menstrual cramps are now described as helpful for PMTS. The 
medication has simply been repackaged, relabeled, or in some 
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cases, given a new title. These products may diminish 
cramps, but are largely ineffective in treating PMTS (PMS 
Access, 1986). 
OTC drugs are intended to be used to treat symptoms of 
minor discomfort or illness. Usually, their aim is to make 
the consumer more comfortable as long as the condition 
lasts, although they include some prophylactic ingredients 
and some ingredients capable of treating and curing certain 
minor conditions (Gilbertson, 1982). However, according to 
O'Brien (1982), it is important to realize that one drug 
does not cure all patients or symptoms. Advertisements for 
OTC products often claim that this is the case. They sug-
gest their product provides relief for all symptoms of PMTS. 
So, how can a PMTS sufferer be sure that an OTC medica-
tion will work or that it is safe? The Food and Drug Admin-
istration (FDA) has been involved since 1972 in a review of 
nonprescription drug products to ensure they contain safe 
and effective ingredients and bear fully informative label-
ing. For most nonprescription drugs there need not be an 
affirmative demonstration that specific formulations of 
active and inactive ingredients are safe and effective 
(Gilbertson, 1982). This loophole is one of the factors 
that motivated this researcher to investigate the effective-
ness of OTC products for PMTS. 
Gilbertson (1982) described the FDA's OTC drug review 
program as a three-phase rulemaking process culminating in 
the establishment of standards for the different nonpre-
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scription therapeutic drug categories. The first phase of 
the process extended over a period of almost ten years and 
was accomplished by an advisory review panel of non-FDA 
experts. The panel reviewed over 14,000 volumes of data 
submitted largely by manufacturers, but also by concerned 
consumers, pharmacists and other interested parties. The 
panel reviewed the drugs to determine whether their ingredi-
ents could be generally recognized as safe and effective for 
use in self-treatment. They were also charged with review-
ing claims and recommending appropriate labeling, including 
therapeutic indications, dosage instructions, and warnings 
about side effects and preventing misuse. 
According to the terms of the review, the panel classi-
fied ingredients as Category I, II or III. Category I drugs 
are generally recognized as safe and effective for the 
claimed therapeutic condition. Category II drugs are not 
generally recognized as safe and effective or have unaccept-
able indications. Category III drugs have insufficient data 
available to permit final classification. 
The panel's findings were reported in the Federal Reg-
ister as an Advanced Notice of Proposed Rulemaking and pub-
lic comment was invited. At the present time the FDA is in 
the second phase of the OTC drug review, which involves the 
FDA's review of the ingredients in each class of drugs, 
based on the outside panel's findings, on public comment, 
and on new data that have become available. This opportu-
nity to provide input into the FDA's rulemaking process was 
46 
another factor that motivated this researcher to investigate 
OTC products for PMTS. 
It appears our country is afflicted with widespread 
chemophilia, a love of chemicals. It would seem people are 
less concerned with modifying behaviors than with finding a 
miracle pill to make them feel better. Pharmaceutical 
companies are partially responsible for this attitude 
because they have successfully promoted the idea that there 
is a pill for every ill, or a chemical solution to every 
physical, emotional, or social problem. These 
pharmaceutical companies invest a significant proportion of 
their profits on advertising to encourage the use of both 
OTC and prescription drugs. 
With respect to OTC menstrual products, the manufactur-
ers market their products based on unsubstantiated claims of 
effectiveness, which women, desperate for relief, believe. 
According to Keye (1985), women with mild premenstrual symp-
toms usually do not report any therapeutic effect from OTC 
drugs. In some cases a product may provide temporary 
relief, but rarely the consistent, long-term relief that 
would enable the PMTS sufferer to exert some measure of con-
trol over her life. 
With all the dubiety surrounding PMTS treatment, this 
investigator questioned how pharmaceutical companies could 
claim their products relieved symptoms of PMTS when no prod-
uct had been proven to be completely successful in alleviat-
ing these symptoms. With knowledge of the FDA's review pro-
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cess the investigator now understands that manufacturers are 
at their own risk and buyers must beware until data are pro-
duced that either confirm or discount the claims being made 
for OTC products for PMTS. Therefore, the purpose of this 
study was to determine if the oral ingestion of eight 
caplets daily, when PMTS symptoms were present, of a product 
containing 500 mg. of acetaminophen, 25 mg. of pamabrom, and 
15 mg. of pyrilamine maleate, would relieve symptoms of 
PMTS. 
This study was conducted as a double-blind cross-over, 
using a 3 x 2 repeated measures analysis of variance with a 
trial factor at three levels (pre-test vs. active treatment 
vs. placebo), and a grouping factor at two levels (birth 
control pill vs. no pill). 
Findings 
Based on the stated hypotheses and the limits of the 
study, the following findings were made: 
1. The oral ingestion of eight caplets per day when 
PMTS symptoms were present had a statistically 
significant effect at the .01 level on the total 
MSQ score in the group of subjects who were not 
using oral contraceptives when the pre-test MSQ 
score was compared to the MSQ score after the 
placebo was administered. Even though the differ-
ence was statistically significant, it had no real 
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practical significance, and was attributed to the 
high placebo response rate associated with PMTS. 
2. The oral ingestion of eight caplets per day when 
PMTS symptoms were present had a statistically 
significant effect at the .05 level on the MSQ 
score for the PMT-A subgroup when comparing the 
pre-test PMT-A score for all subjects with the 
PMT-A score for all subjects after the placebo had 
been administered. Even though the difference was 
statistically significant it had no real practical 
significance due to the fact that the difference 
occurred after the administration of the placebo. 
3. The oral ingestion of eight caplets per day when 
PMTS symptoms were present had a statistically 
significant effect at the .05 level on the MSQ 
score for the PMT-H subgroup in the group of sub-
jects who were not using oral contraceptives. 
However, a subsequent Newman-Keuls post hoc analy-
sis revealed no pairs of means to be significantly 
different from one another. 
4. The oral ingestion of eight caplets per day when 
PMTS symptoms were present had a statistically 
significant effect at the .05 level on the MSQ 
score for the PMT-C subgroup in the group of sub-
jects who were not using oral contraceptives. A 
Newman-Keuls post hoc analysis revealed no pairs 
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of means were significantly different from one an-
other. 
5. The oral ingestion of eight caplets per day when 
PMTS symptoms were present had no significant ef-
fect when comparing the group of women using oral 
contraceptives and the group not using oral con-
traceptives. 
conclusion 
Based on the results of this study, this investigator 
concluded that the active treatment in this study does not 
provide relief for women who have moderate-to-severe PMTS. 
Recommendations 
It would seem that the status of the OTC drug under 
investigation needs to be reclassified from category I to 
Category II. The results of this study indicated that the 
active treatment in this study, which consists of 500 mg. of 
acetaminophen, 25 mg. of pamabrom, and 15 mg. of pyrilamine 
maleate, and is presently being marketed as an OTC medica-
tion for PMTS, does not provide effective relief for the 
symptoms of PMTS. However, it should also be noted that 
other studies which investigated similar products (Wisconsin 
study, 1978; McColl and Durkin, 1981) produced results which 
indicated pamabrom and pyrilamine maleate by themselves, and 
in combination, reduced the symptoms of PMTS. 
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The reasons for the conflicting evidence that continues 
to come out of studies involving PMTS treatments are many. 
This particular area of research is fraught with methodolog-
ical barriers and because of this no one is able to offer 
effective treatment at this time. The methodological flaws 
that plague PMTS research form the basis for recommendations 
for future research. 
First and foremost, the underlying cause of PMTS must 
be discovered before effective treatment can be offered. 
Once the cause is determined then an exact definition for 
PMTS can be developed and an objective instrument for mea-
suring the presence and severity of PMTS symptoms can be 
constructed. If these three recommendations can be accom-
plished, much of the confusion surrounding PMTS will be 
resolved. 
However, until the time comes that a cause, a defini-
tion, and an objective instrument can be developed, the fol-
lowing recommendations would improve research in this area: 
1. Most importantly, future studies must use placebo-
controlled, double-blind formats in all research 
into the efficacy of drugs for the symptoms of 
PMTS. 
2. The use of small, heterogeneous sample sizes must 
be avoided. 
3. The length of the studies must be increased to at 
least six consecutive months to reduce the impact 
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of the variability of symptoms from month-to-
month. 
4. Control over extraneous variables, such as diet, 
stress, exercise, and other drugs needs to be 
tightened to reduce the impact on the experimental 
treatment being investigated. 
Finally, from a practical perspective, following are a 
number of recommendations from Harrison, Sharpe and Endicott 
(1985) for those women who continue to be frustrated by the 
PMTS treatment dilemma: 
1. Initial therapeutic management should consist of 
education and support along with a thorough 
physical and psychological exam. 
2. A regular menstrual cycle calendar/diary should be 
kept so activities can be planned around the 
premenstrual phase and also so that understanding 
can be increased regarding specific symptoms. 
3. Nutritional evaluation and counseling are neces-
sary so troublesome foods that contain salt, sugar 
and caffeine can be avoided. 
4. For particularly persistent or severe symptoms, 
pharmacologic treatment is recommended. 
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INFORMED CONSENT FORM 
By signing this document you are agreeing to 
participate in an experimental research study. The purpose 
of this research is to determine the effectiveness of an 
over-the-counter product in the treatment of premenstrual 
distress. If you qualify and agree to participate in the 
study you are advised that the study will take place over 
two consecutive months. 
To qualify for the study you will initially fill out a 
Menstrual Symptom Questionnaire (MSQ) to determine the 
presence and severity of symptoms you have that are 
associated with premenstrual distress. If your MSQ score 
meets the established criteria for inclusion in this study, 
you will then be randomly assigned to one of two groups. 
Both groups will receive two different treatments, an over-
the-counter product and a placebo in a double-blind 
crossover fashion. Double-blind means neither you or the 
investigator will know which of the two treatments you will 
be receiving. Crossover means you will receive the over-
the-counter product one month and the placebo one month. 
If you are in one of these treatment groups you will be 
asked to begin taking the treatment on day one of the onset 
of premenstrual distress and continue taking the recommended 
daily dosage until the onset of menses. The recommended 
daily dosage is two caplets with water every four hours with 
a maximum daily dosage of eight caplets per day. For this 
study you will take the maximum daily dosage of eight 
caplets per day. 
After the treatment period is over you will be asked to 
fill out a MSQ to evaluate the effect of the treatment on 
your premenstrual symptoms. This procedure will take place 
over two consecutive months. 
The active treatment in this study is a commercial 
product whose trademark is to remain confidential to the 
investigator. This treatment, which is available as an 
over-the-counter product, consists of 500 mg. of 
acetaminophen, an aspirin-like substance used for relief of 
pain; 25 mg. of pamabrom, a diuretic that relieves water 
retention and pyrilamine maleate, an antihistamine that has 
pain-dulling properties. The other treatment to be used in 
this study is a placebo containing an inert substance, 
lactose, a milk sugar. 
The Food and Drug Administration's Advisory Review 
Panel on over-the-Counter Miscellaneous Internal Drug 
Products reviewed data on over-the-counter menstrual drug 
products containing a diuretic (pamabrom), an antihistamine 
(pyrilamine maleate) and an analgesic (acetaminophen). The 
Panel classified the combination, as well as the individual 
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ingredients, as Category I for relieving symptoms of 
premenstrual syndrome. A category I designation by the 
Panel indicates conditions under which over-the-counter 
menstrual drug products are generally recognized as safe and 
effective and are not misbranded. However, you should be 
advised that even though these products have been labeled as 
safe and effective by the Food and Drug Administration, 
there may be side effects. 
The Panel found acetaminophen relatively free of 
adverse effects and the only known contraindication to the 
use of acetaminophen is hypersensitivity to the drug. The 
side effects of antihistamines may include mild sedation, 
listlessness, irritability and loss of appetite. Pamabrom 
has shown no evidence of significant toxicity or adverse 
reactions since it was approved for over-the-counter 
marketing in 1952. 
Your participation in this experiment is voluntary and 
confidential and you may withdraw without prejudice at any 
time. You will not receive any compensation for your 
participation in this experiment and you will be responsible 
for any medical expenses you may incur. 
If you experience any physical discomfort as a result 
of your participation in this experiment, please contact Dr. 
Alice Gambill or Dr. Donald Cooper, physicians at the 
Oklahoma State University Student health Center. Dr. 
Gambill and Dr. Cooper will be available from 8am-5pm, 
Monday through Friday. You can also contact Dr. Gambill by 
phone at 624-7019 and Dr. cooper at 624-7031. 
If any problems occur between the hours of 5pm-8am or 
on weekends, you can contact the Emergency Room at the 
student Health Center and tell the staff you are part of an 
experiment involving Dr. Gambill and Dr. Cooper and they 
will contact the physician for you. 
If you have any questions regarding your participation 
in this study please feel free to ask the investigator now 
or at any time during the experiment. 
Subject Date Investigator Date 
Witness Date 
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MENSTRUAL SYMPTOM QUESTIONNAIRE (MSQ) 
Name: 
---------------------------------------------------------------
Age: _____ _ Height: ____ _ Weight: _____ _ 
Marital Status: Single Married ______ Divorced ______ Widowed 
Present Contraception: None Pill ___ IUD ______ Other 
History of taking contraceptive pills: __ Yes No If yes, months ago: __ 
For how long: __ months. Number of Pregnancies: __ Children: 
How long have you suffered from premenstrual complaints: ______ years 
Sedative 
-------
____ .Antidepressant Previous treatment: None 
__ Water pills __ Birth control pills __ Progesterone __ Bromocriptine 
__ Primrose oil Other (specify): -------------------
Duration of previous treatment: ___ months. Last treatment _____ months ago 
Response to treatment: ___ Excellent ___ Good Worse 
----
None 
---
Have you ever been diagnosed as having endometriosis? Yes 
----
No 
----
Are you presently taking any other prescription or over-the-counter medications? 
Yes No If yes, specify: ------------------
Your last period started ______ (date). Your last period lasted ____ days. 
Your last menstrual cycle was ____ days long. Your last period was: 
___ Light ____ Moderate ___ Heavy 
Occupation: -------------------------------------------
Grading of Symptoms and Grading 
of Effects of PMT on Performance 
0 - No Effect. 
1 - Mild - Present, but does not interfere with 
performance at home, at work and during social 
activities. Not noticeable by others. 
2 - Moderate - Interferes with familial, marital, social and 
work-related activities. Able to function without 
medication at a lower level of performance. Noticeable 
by others. 
3 -Severe - Disabling. Marked interference with and 
complete disruption of familial, marital, social and work-
related activities. Unable to function without medication. 
Very noticeable by others. 
Grade Your Symptoms For last 
Menstrual Cycle Only 
SYMPTOMS 
Nervous tension 
Mood swings 
Irritability 
Anxiety 
Weight Gain 
Swelling of 
extremities 
Breast tenderness 
Abdominal bloating 
Headache 
Craving for sweets 
Increased appetite 
Heart pounding 
Fatigue 
Dizziness or 
fainting 
Depression 
Forgetfulness 
Crying 
Confusion 
Insomnia 
TOTAL MSQ SCORE 
Week 
After 
Period 
Week 
Before 
Period 
Total__ Total __ 
Total__ Total __ 
Total __ Total __ 
Total__ Total __ 
Grade the Effects of PMT on Performance 
For Last Menstrual Cycle Only 
ACTIVITY 
Marital 
Familial 
Social 
Work-Related 
Week 
After 
Period 
Week 
Before 
Period 
Grade the Effects of the Treatment on 
Performance for last Menstrual Cycle Only 
-1 =Worse 
0 =No effect 
1 = Slight improvement 
2 = Moderate improvement 
3 = Marked improvement 
ACTIVITY 
Marital 
Familial 
Social 
Work-Related 
Week 
After 
Period 
Week 
Before 
Period 
Using the above scale how would you grade the effects 
of the treatment on the relief of the symptoms of 
menstrual distress-------
Did you follow the dosage recommendations: 
__ Never __ Rarely 
__ Most of the time __ Nways 
Any side effects while on the treatment? (specify) 
Comments: --------------
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